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ABSTRACT  
The CYP4F2 gene is known to influence mean coumarin dose. The aim of the present study was to 
undertake a meta-analysis at individual patients’ level to capture the possible effect of ethnicity, 
gene-gene interaction or other drugs on the association and to verify if inclusion of CYP4F2*3 
variant into dosing algorithms improves the prediction of mean coumarin dose. We asked the 
authors of our previous meta-analysis (30 articles) and of 38 new articles retrieved by a systematic 
review to send us individual patients’ data. The final collection consists 15,754 patients split into a 
derivation and validation cohort. The CYP4F2*3 polymorphism was consistently associated with an 
increase in mean coumarin dose (+9% (95%CI 7-10%), with a higher effect in females, in patients 
taking acenocoumarol and in Whites. The inclusion of the CYP4F2*3 in dosing algorithms slightly 
improved the prediction of stable coumarin dose. New pharmacogenetic equations potentially useful 
for clinical practice were derived.  
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INTRODUCTION 
Coumarins have proved to be effective in the treatment of thromboembolic disease and despite the 
introduction of direct oral anticoagulants, they remain one of the most widely prescribed family of 
drugs worldwide.
1
  
The narrow therapeutic index and high inter-individual variability in therapeutic dose make 
coumarin therapy difficult to manage. Many studies have showed two genes, CYP2C9 and 
VKORC1, that are associated with variation in warfarin, phenprocoumon and acenocoumarol 
maintenance doses requirement and have suggested some clinical benefits from genotype-guided 
dosing.
2
 On the basis of such data, the Food and Drug Administration (FDA) has updated the label 
for warfarin twice, advising that two variants in the CYP2C9 gene (C144R and I359L) and one in 
the VKORC1 gene (G-1639A) might be taken into consideration when initiating warfarin therapy 
(Warfarin (Coumadin) product labeling, FDA. http://www.accessdata.fda. 
gov/drugsatfda_docs/label/2011/009218s107lbl.pdf.).  
Although there have been contradictory results in randomized clinical trials (RCTs) about the utility 
of genotype-guided dosing of coumarin drugs when compared with either standard clinical care or 
clinical algorithms,
3-5
 a recent RCT in patients undergoing elective hip or knee arthroplasty
6
 showed 
superiority of genetic dosing compared with clinical dosing.  Some but not all meta-analyses have 
also shown an improvement in clinical endpoints such as bleeding events.
3,7-11
 Moreover, none of 
the trials included in the meta-analyses included CYP4F2*3 polymorphism (1347C>T;  
c.1297G>A; p.Val433Met; rs2108622), whose effect on coumarin dose was discovered later when 
compared with CYP2C9 and VKORC1.   
Our previous meta-analysis performed on aggregate data from 30 studies, showed that CYP4F2 
variation was associated with nearly 8% higher coumarin doses in T allele carriers. Indeed, a 
possible gene-gene interaction and an effect of race on the genetic effect was detected.
13
 Despite the 
low effect size, CYP4F2 is currently regarded as the third most influential genetic locus with respect 
to coumarin drug maintenance dose. Older studies, which compared pharmacogenetic algorithms 
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with either clinical-based algorithms or fixed dose approach, did show a possible improvement in 
prediction only in selected subgroups.
14,15
 The incorporation of CYP4F2 into existing models might 
improve the accuracy of dose prediction with coumarins.
16,17
 Recently, the Clinical 
Pharmacogenetics Implementation Consortium updated the guidelines for CYP2C9 and VKORC1 
genotypes and warfarin dosing including evidence from the published literature for the non-
synonymous variant CYP4F2*3 (1347C>T; c.1297G>A; p.Val433Met; rs2108622) which was 
found to be significantly associated with altered dose requirements for coumarin anticoagulants.
2
 In 
order to clarify the actual clinical utility of including the CYP4F2 polymorphism into 
pharmacogenetic dosing algorithms, some essential information is needed. Thus, we performed a 
meta-analysis at individual patients’ level to understand the real effect size of this polymorphism 
and to test how much either a possible gene-gene interaction or the effect of ethnicity or other 
covariates could modify the pharmacogenetic association and prove to be useful in creating new 
pharmacogenetic equations. We hereby provide the largest meta-analysis of CYP2C9, VKORC1 and 
CYP4F2 polymorphisms affecting the dose of warfarin and acenocoumarol in samples collected 
from 25 different countries, including more than 15,000 participants treated with coumarin drugs. 
New pharmacogenetic equations potentially useful for clinical practice have been derived for 
different ethnic groups. 
 
RESULTS 
Characteristics of included studies 
Starting from the 30 articles included in our previous meta-analysis (search from inception till 
August 2011), individual patient data were obtained from 19 studies.
12,18-35
 From one co-author we 
obtained an additional dataset related to an article not previously included because no data about the 
CYP4F2 polymorphism were present in the original publication.
36
 From the group of 38 articles 
retrieved from the new search (from September 1, 2011 to September 14, 2016), individual patient 
data were obtained from 18 studies.
16,17,37-52
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Thus, 38 articles were included in the present work from authors who agreed to share individual 
patient data: 20 from the first systematic search, 18 from the second systematic search.  Data from 
one study were divided into two distinct cohorts according with the main author subdivision of 
sample into discovery and validation cohorts.
46 
Moreover, data from two studies had been collected 
in one cohort.
16,43
 Finally, data from one study was divided into two cohorts, one cohort treated with 
acenocoumarol and the other with phenprocoumon treatment.
44
 This resulted in 39 cohorts were 
considered for the meta-analysis including a total of 15,754 patients. Characteristics of the 
individual studies are summarized in Table 1. Thirty-one cohorts examined the association between 
CYP4F2 polymorphism and the maintenance dose of warfarin, 7 cohorts evaluated this association 
for acenocoumarol and one for phenprocoumon. Information on CYP4F2, VKORC1 and CYP2C9*3 
genotyping were available for all 39 cohorts, while CYP2C9*2 genotype was recorded for 35 out of 
the 39 (89.7%) cohorts. All studies but one
19
 included both male and female participants with a 
minimum of 24% males. One study selected very elderly patients (mean age 86.7 years).
35
 Data on 
BMI and drugs known to potentially interfere with warfarin were available for 31 and 27 cohorts 
respectively. All studies were published between 2006 and 2016.  
 
Association between CYP4F2*3 polymorphism and stable coumarin dose  
Figure 1 shows the forest plot for the difference in log dose of warfarin for subjects with at least 
one T-allele (CT+TT) CYP4F2 as compared to wild-type (CC) subjects, according to a dominant 
model. The estimated effect size was 0.09 (95%CI 0.07 to 0.10), corresponding to a 9% increase in 
mg/week (95%CI 7-10%). The funnel plot (see Figure S1) is compatible with no effect of bias on 
publication.  
Separate estimates for CT and TT CYP4F2 genotypes are reported in Figure S2: the estimated 
effect size for CT vs CC subjects is 0.07 (95%CI 0.06 to 0.08), corresponding to a 7% increase in 
mg/week; while for TT vs CC subjects it is 0.17 (95%CI 0.15 to 0.19), corresponding to a 19% 
increase in mg/week. In Table 2 the analysis of the available subgroups highlights that the effect of 
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the CYP4F2*3 polymorphism is significant in Whites and Asians but not in Blacks and other ethnic 
groups. Moreover, there was a significant difference by gender for the effect of the CYP4F2 
polymorphism on coumarin dose (the effect is significantly higher in females) and by type of 
coumarin drugs (the effect was lower for warfarin as compared to acenocoumarol). No significant 
difference in the effects of smoking, target INR, adjustment for other drugs, consistency of 
genotype frequencies with the HW equilibrium, quality score and other polymorphisms was found 
(Table 2). The figures for the different meta-analyses in subgroups are presented in Figure S3 and 
S4. 
 
Stable coumarin dose predictive model 
Table 3 presents the predictive model for logarithm of stable coumarin dose according to patients’ 
clinical and genetics characteristics. As statistical test for model fit (R
2
) is reported for both the test 
and validation cohorts. Looking at our calculated model on the whole dataset, adjusted R
2
 was 
slightly higher for models including CYP4F2*3 polymorphisms than for models without CYP4F2*3 
for all the ethnic groups except Blacks (for warfarin dose, adjusted R
2 
for models with and without 
CYP4F2*3 polymorphism were, respectively, 0.51 and 0.50 for Whites; 0.43 and 0.42 for Asians; 
0.27 and 0.27 for Blacks). For cohorts that included Black patients, addition of the CYP2C9*5 SNP 
to the models did not result in substantial improvement of the adjusted R
2 
(Table 3). Further 
prediction models also including concomitant drugs (amiodarone, etc.) and smoking habits are 
presented in Table S1. 
Beta coefficients for single gene and gene-gene interaction are presented in Table 4 for each 
ethnicity and drug subgroups.  
The effect of potentially interacting drugs could be evaluated only on a subsample of the cohorts 
and is presented in Table S2. Patients taking amiodarone or drugs classified as CYP inhibitors 
required a lower dose whereas patients taking CYP inducers required a higher dose of coumarin 
drugs. If the effect of the drugs was considered, the beta estimate for CYP4F2 and the other SNPs 
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varied slightly but remained significant for most analyses. No significant interaction between SNPs 
and drugs were detectable apart from CYP2C9*2 and rifampin and all CYP inhibitors and all CYP 
inducers in Whites consuming acenocoumarol. Another weak but nominally significant interaction 
was present between CYP2C9*2 and statin or aspirin in Black patients on chronic warfarin therapy 
(Table S2). 
The comparison of R2 of our model with those calculated for two previously published models are 
reported in Table S3 and are basically comparable, ranging from 0.41 to 0.47 for Whites, 0.44 for 
Asians and from 0.23 to 0.33 for Blacks. 
 
DISCUSSION 
In our previous meta-analysis on the effect of the CYP4F2 rs2108622 (1347C>T; c.1297G>A; 
p.Val433Met; CYP4F2*3) we found that the estimated effect size was nearly 10%. In this 
individual patient data meta-analysis we have not only confirmed this finding in a larger cohort of 
primary studies that include all the available study-specific covariates, but can add other important 
findings. Contrary to what was found in the first meta-analysis, a slight but significant effect of 
gender was so identified such that males had a lower effect of the T-allele when compared to 
females. Indeed, a higher dose of coumarin drugs was needed in carriers of the T-allele if they were 
Whites or Asians but not in Blacks or in other ethnic groups (Indians, Browns from Brazil, 
Egyptians), but the latter is probably a reflection of the lower sample size. We also identified 
differences between different coumarin drugs: patients taking acenocoumarol and carrying the T-
allele needed a higher dose of the drug when compared with patients taking warfarin and carrying 
the same polymorphism. 
There was no effect of other possible important covariates, such as smoking, age and indication for 
coumarin, and no interactions with the other relevant polymorphisms were found.  
Evaluation of the beta estimate of the tested SNPs, confirmed that the larger effect is due to the 
VKORC1 followed by CYP2C9, while CYP4F2 had a limited effect size. 
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Looking at primary studies, the large majority of them are in line with the results of the meta-
analysis and only 4 out of the 39 have a central point of the estimate below the 0 line. Even the 
point estimate for the effect of CYP4F2 is not so different between primary studies. the extremes 
being the study performed by Borgiani with a +0.26 estimate and the one by Isaza with a -0.05 
which however have a 95%CI which is around to +0.07, not far from our total effect size (slightly 
less than 10%).
18,48
  
However, the funnel plot shows a certain asymmetry, almost significant when analysed using 
Egger’s. It is therefore possible that unpublished negative studies could affect the real estimate of 
the effect of the CYP4F2*3 polymorphism. 
Differently from our previous meta-analysis, we could add also drug as moderating parameters at 
least in some subgroups and, as expected, this evaluation decreased heterogeneity. 
The functionality of the CYP4F2 polymorphism has been shown in relation to the production of 20-
HETE derived by arachidonic acid and in differences in mRNA production by liver cells in carriers 
of different alleles.
53
 
The interaction of the CYP4F2 polymorphism with sex is not unexpected: also in other studies 
exploring other cardiovascular actions, some CYP polymorphisms have shown a differential effect 
in males and females probably due to an interaction with either androgens or estrogens.
54
 Even in 
animal models these differences are evident, at least for blood pressure determination.
54
 
Due to our large sample size, we could calculate and subsequently validate different prediction 
models, that included the effect of the CYP4F2*3, the other well-known polymorphisms of 
CYP2C9 and VKORC1, and the other covariates differentiating the effect of gender and ethnicity 
and obtaining discrete coefficient of determinations that indicate a good fit of the models. Other 
predictive pharmacogenetics equations estimating coumarin dose have been developed using large 
samples sizes,
14,15
 but both the International Warfarin Pharmacogenetics Consortium and the 
“Warfarin dosing” equations used only CYP2C9 and VKORC1 genetic variation to estimate 
warfarin dose and the R
2
 estimate for the final model (which also included amiodarone), obtaining 
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values of 0.47 and 0.53 respectively. These results are in line with our data for white subjects but 
our results are more generalizable since multiple cohorts from Europe were also included. In fact, 
Gage’s equation is derived from a more homogeneous group of patients collected in 3 centers in the 
US (St. Louis, San Antonio and Gainesville) with a 4
th
 trial included in the validation cohort.
14
 By 
contrast, the International Warfarin Pharmacogenetics Consortium (IWPC) collected 21 research 
groups from 9 different countries and finally include only patients with a target INR between 2-3 
(n=5,052). Their final model was not divided according to ethnicity but instead the ethnicity 
variable was added in the model. Indeed, outlier patients were excluded from the final analysis. It is 
worth mentioning that the final sample size of our study is more than 2 times the previous studies 
for warfarin and we have also calculated predictive models for acenocoumarol.  
Even if newer anticoagulants have substantially changed clinical practice especially in developed 
countries, the use of coumarin drugs is still widespread in the world, so that equations like the one 
derived from our study will be clinically useful for many years. in the importance of genotype has 
been further shown in the ENGAGE AF-TIMI 48 trial, which compared the clinical efficacy of 
edoxaban, a direct oral anticoagulant, with warfarin, in a pre-specified genetic sub-analysis. 
Stratification of patients according to CYP2C9 and VKORC1 polymorphisms revealed that the three 
groups identified, normal responders, sensitive responders, and highly sensitive responders, the last 
group were found to spend a greater proportion of time over-anticoagulated compared with normal 
responders, but only for the first 90 days of treatment.
55
 
RCTs using not only the CYP2C9 and VKORC1 polymorphism but also the CYP4F2 polymorphism 
have recently been performed. In non-valvular atrial fibrillation no apparent advantage was found 
for the group randomized to genotype base dose
56
 but in a recent trial in patients aged 65 years or 
older initiating warfarin for elective hip or knee arthroplasty conducted at 6 US medical centers, 
genotyping reduced the combined risk of major bleeding, INR of 4 or greater, venous 
thromboembolism, or death.
6
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In another trial that compared a genotype-guided algorithm vs physician management for the 
initiation of acenocoumarol, a higher proportion of patients in the genetic group reached and 
maintained a steady dose than patients randomized to routine practice when starting oral 
anticoagulation.
57
  
 
Limitations and strengths of the study 
Our individual-data meta-analysis has limitations. First, although we applied a sensitive search 
strategy for the retrieval of potentially eligible studies, we cannot rule out the possibility that some 
relevant studies might not have been included. Indeed, not all the potentially eligible studies were 
added to the meta-analysis because the authors did not share individual patient’ data. Second, 
adjustment for certain covariates such as amiodarone was possible in only a limited sample of 
patients. The quality score of the included studies was heterogeneous, ranging from 3 to 7 (median: 
5), but this did not affect CYP4F2*3–coumarin dose association, since we found no statistically 
significant difference in the estimates for studies with lower and higher quality score. Finally, our 
genotyping-based algorithms in Blacks have low predictivity even including the CYP2C9*5 
polymorphism, probably because we could not include more variants in CYP2C9 that were 
demonstrated to be especially important in this ethnic group.
2
 Since the exclusion of specific 
CYP2C9 variants from the dosing algorithm in Blacks can lead to overdosing, we would 
recommend against the use of the specific dosing algorithms in patients of African ancestry
2
 until 
more specific algorithms have been developed. 
Strengths of our collaborative study are the large sample size with several ethnic groups allowing 
for generalizability of the results and the possibility to have equations not only for warfarin but also 
for acenocoumarol based on a quite large sample size. The heterogeneity was low possibly because 
most of the variables associated with mean coumarin dose have been considered in our models. 
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Conclusion 
In conclusion, we have undertaken the largest individual patient data meta-analysis, including the 
CYP4F2 polymorphism, in patients taking warfarin or other coumarin drugs. Our data show that the 
CYP4F2 rs2108622 polymorphism affects the dose requirements of these drugs in Whites and 
Asians but not in Blacks or other ethnic groups. We also provide reliable prediction models that can 
guide physicians to estimate the stable dose of warfarin according to genotypes, anthropometric and 
demographic factors, ethnicity, and the use of other drugs.    
Anyhow, since RCTs, that tested genetic prediction models with the CYP4F2*3 SNP, showed 
contradictory results
6, 56
, the utility of these models in clinical practice need to be established in 
further RTCs before their widespread utilization in clinical settings.  
 
METHODS 
Search strategy and eligibility criteria 
The 30 articles included in our previous meta-analysis were considered all potentially eligible for 
the present study.
13
 To expand our search to articles published after the date fixed for final inclusion 
in the previous meta-analysis, we searched Medline and Web of Science from September 1, 2011 to 
September 14, 2016 by applying the same search algorithm used previously (see Supplementary 
Material) and found 38 additional studies that could potentially be included (see flow diagram) 
according to the inclusion criteria (see Supplementary Material). All 68 studies evaluated for 
inclusion were clinical cohort or cross-sectional studies that have performed genotyping of CYP4F2 
in combination with CYP2C9 (at least one out of the two variants of interest) and/or VKORC1 in 
coumarin treated patients. As per our previous study, we considered the following polymorphisms: 
rs2108622 (1347C>T; 1297G>A; p.Val433Met; CYP4F2*3) for CYP4F2, rs1799853 (430C>T) 
and rs1057910 (1075A>C) for CYP2C9 (also known as CYP2C9*2 and CYP2C9*3); rs9923231 
(−1639 G>A) for VKORC1. In relation to the latter variant, we also included data from studies that 
used the two alternative polymorphisms: rs9934438 (1173C>T) in the VKORC1 gene which is in 
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complete linkage disequilibrium (LD) with the reference polymorphism and rs10871454 (-
1168C>T) located in the Syntaxin 4 A–placental (STX4A) gene, flanking the VKORC1 gene, which 
showed a LD of 0.99 with the reference polymorphism. 
In our previous analysis, consistent with published studies, the performance of our regression was 
low, especially in Blacks, where an effect of other SNPs especially in CYP2C9 is considered 
important. Thus, in the 5 cohorts where at least the CYP2C9*5 variant was available we repeated 
the analysis by adding this polymorphism. 
 
Data collection 
We asked the first/last or corresponding authors of the retrieved primary studies to participate in a 
collaborative meta-analysis on individual patient data. Authors who were willing to collaborate 
were finally included if their original database contained the following mandatory data for single 
patients: sex, age, race, genotypes, indication for coumarin therapy, INR target, type of coumarin 
used and maintenance dose. Additional information on body weight, height and use of interacting 
drugs were also recorded when available. Each cohort has been assigned to one single study unless 
otherwise specified. For studies containing overlapping samples we considered the first published 
study or the one that enrolled the largest number of patients. Data were harmonized into a pooled 
database. Two researchers (ED and MM) cross-checked trial details provided by the authors against 
published articles. Any inconsistencies were discussed with the original trialists and corrections 
were made when appropriate. As for our previous meta-analysis, we graded the quality of 
epidemiologic studies in general, applying items taken from the Newcastle–Ottawa Quality 
Assessment Scale for Cohort Studies indicators specific to the quality of genetic association studies, 
and indicators specific for coumarin (e.g., stable anticoagulation). Quality assessment also included 
departure from Hardy–Weinberg equilibrium, that was calculated by the Chi Square test in controls. 
We applied a scale with a maximum score of 7 points (see Supplementary Material for details).  
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Statistical analysis 
Two-stage analysis for the association between CYP4F2*3 polymorphism and stable coumarin 
dose  
We calculated study-specific estimates, with 95% Confidence Intervals (CI), for the difference in 
log dose of coumarin for subjects with at least one CYP4F2 T-allele (CT+TT) compared to wild-
type (CC) subjects, according to a dominant model. Separate estimates for CT and TT genotypes 
were also calculated as a sensitivity analysis. These study-specific estimates were obtained by 
fitting general linear models with log dose of coumarin as the dependent variable and CYP4F2*3 
polymorphism as the independent variable. All the models were adjusted for available study-
specific covariates, including: age, sex, race, BMI, smoking status, indication for coumarin 
treatment, INR target, concomitant drugs, CYP2C9*2 and *3 polymorphisms, and VKORC1 
polymorphism. 
Following the two-stage analysis approach, we pooled study-specific estimates with random-effects 
models, using the DerSimonian and Laird method (see Supplementary Methods). We evaluated 
homogeneity among study-specific estimates by the Q statistic and I
2
, which represents the 
percentage of total variation across studies that is attributable to heterogeneity rather than to chance 
(see Supplementary Methods). We performed meta-regression analysis to assess the influence on 
Summary Estimates (SE) of different study features: type of drugs (acenocoumarol/warfarin), sex, 
ethnicity (Whites/Asians/Blacks/Others), INR target (<2.5/2.5/>2.5), current smoking status, study 
adjustment for concomitant drugs (yes/no), deviation from Hardy-Weinberg (HW) equilibrium, 
quality score (<5/≥5), CYP2C9*2/*3 (wild-type/any polymorphism) and VKORC1 (wild-type/any 
polymorphism). When significant differences according to specific study factors were suggested by 
meta-regression, stratified analyses were performed for CYP4F2*3-coumarin dose association on 
subgroups of significant factors. 
We assessed possible participation bias by drawing funnel plots and by Egger's test (see 
Supplementary Methods). 
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P-values <0.05 were considered statistically significant for all the tests apart from the Q statistic, 
where p-values<0.10 were considered statistically significant. The analysis was carried out using 
the SAS (version 9.4) and STATA (version 13) software. 
 
Stable coumarin dose predictive model 
Due to significant differences in coumarin dose and CYP4F2*3 association for different drugs and 
ethnic groups, the individual data analysis on the pooled dataset was always reported for each type 
of drug (acenocoumarol/warfarin) and for each ethnic group.  
For each ethnic and drug subgroup, we randomly chose 2/3 of patients as the “derivation cohort” for 
developing dose-prediction models, while the remaining 1/3 of the patients constituted the 
“validation cohort,” which was used for testing the final selected model. In order to keep a large 
sample size for prediction model construction, we included covariates which were available in the 
majority of studies (Table 1): age, BMI, sex, indication for treatment, CYP4F2*3, CYP2C9*2, *3 
and *5 (for Blacks), and VKORC1 polymorphisms, by using general linear models with log dose of 
coumarin as dependent variable. To use an additive genetic model, we coded the number of variant 
alleles at each locus as 0, 1, or 2. Sensitivity analyses were also conducted on the whole cohort of 
subjects by including further available covariates collected in a smaller number of studies 
(concomitant drugs, especially amiodarone, and smoking status), to assess their role in stable 
coumarin dose prediction. The coefficient of determination (R
2
) was calculated both for the main 
prediction model on the “derivation cohort” and for models included in sensitivity analyses. We 
applied the scores obtained from the main prediction model to the validation data set and also 
calculated the R
2 
.  
For the sake of comparison, we also applied scores obtained from two previously published models 
for warfarin dose prediction
14,15
 to our validation cohort and converted the scores to units of 
mg/week. In order to correctly compare our proposed model with each of the two previously 
published models, R
2
 was calculated on the subset of subjects for whom both scores could be 
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calculated on the basis of available data. In order to assess the importance of CYP4F2*3 on 
warfarin dose prediction in our data, we also compared dose predictions from our pharmacogenetic 
model including CYP4F2*3 in the whole dataset with that from our model excluding CYP4F2*3 by 
using the adjusted R
2
 as defined by Darlington (see Supplementary Methods).  
Gene-gene and gene-drug interactions were investigated by adding an interaction term to the main 
prediction model fitted on the whole cohort of subjects (for each drug/ethnicity subgroup), in order 
to have the largest sample size to test for interaction. Moreover, we performed subgroup analyses 
according to the use or not of specific concomitant drugs, to evaluate whether the change in 
coumarin dose associated with specific gene polymorphisms were modified by concomitant drugs.  
The assumption of exchangeability for this analysis was briefly discussed in the Supplementary 
Methods. P-values <0.05 were considered statistically significant. The analyses were carried out 
using SAS (version 9.4) software. The SAS code is available as Supplementary Material.  
 
Study Highlights: 
 What is the current knowledge on the topic? 
Coumarin drugs have a narrow therapeutic index but single nucleotide polymorphisms in the 
CYP2C9 and VKORC1 genes may help in predicting the dose. 
 What question did this study address? 
Do genetic algorithms including the CYP4F2*3 SNP perform better than old ones in predicting 
mean coumarin dose? 
 What does this study add to our knowledge? 
 In this single-patient meta-analysis we confirm that CYP4F2*3 influences mean coumarin 
dose especially in females, in patients taking acenocoumarol and in Whites, but with a low 
effect size. 
 How might this change clinical pharmacology or translational science? 
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 New pharmacogenetics equations potentially useful for clinical practice have been derived 
for different ethnic groups. 
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Figures legends 
Figure 1. Forest plot for the difference in logarithm of stable coumarin dose* for subjects with 
CYP4F2 polymorphism (CT+TT) compared to subjects with CYP4F2 wild-type (CC), according to 
dominant model.  
 
Figure 2. Flow diagram. 
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